Jennifer E. Sager

1.5k total citations · 1 hit paper
19 papers, 826 citations indexed

About

Jennifer E. Sager is a scholar working on Pharmacology, Infectious Diseases and Pharmacology. According to data from OpenAlex, Jennifer E. Sager has authored 19 papers receiving a total of 826 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pharmacology, 6 papers in Infectious Diseases and 5 papers in Pharmacology. Recurrent topics in Jennifer E. Sager's work include Pharmacogenetics and Drug Metabolism (8 papers), SARS-CoV-2 and COVID-19 Research (5 papers) and COVID-19 Clinical Research Studies (4 papers). Jennifer E. Sager is often cited by papers focused on Pharmacogenetics and Drug Metabolism (8 papers), SARS-CoV-2 and COVID-19 Research (5 papers) and COVID-19 Clinical Research Studies (4 papers). Jennifer E. Sager collaborates with scholars based in United States, United Kingdom and Canada. Jennifer E. Sager's co-authors include Nina Isoherranen, Isabelle Ragueneau‐Majlessi, Jingjing Yu, Yoshiyuki Shirasaka, Justin D. Lutz, Connie L. Davis, Lauren Price, K. Linnea Welton, Matt Kaeberlein and Brian K. Kennedy and has published in prestigious journals such as Antimicrobial Agents and Chemotherapy, Biochemical Pharmacology and Clinical Pharmacology & Therapeutics.

In The Last Decade

Jennifer E. Sager

18 papers receiving 812 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification

2015 384 citations Jennifer E. Sager, Jingjing Yu et al. Drug Metabolism and Disposition profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jennifer E. Sager United States	10	325	167	155	149	120	19	826
Stephen P Adams Canada	19	344 1.1×	190 1.1×	386 2.5×	60 0.4×	68 0.6×	36	1.4k
Noriko Ohashi Japan	14	313 1.0×	182 1.1×	243 1.6×	115 0.8×	116 1.0×	27	1.1k
Louis Leung United States	16	287 0.9×	163 1.0×	195 1.3×	75 0.5×	124 1.0×	24	754
S. Irie Japan	12	234 0.7×	326 2.0×	88 0.6×	169 1.1×	74 0.6×	17	819
John Dikran Balian United States	8	383 1.2×	192 1.1×	178 1.1×	78 0.5×	92 0.8×	10	744
Ernst‐Ulrich Griese Germany	19	895 2.8×	472 2.8×	334 2.2×	259 1.7×	216 1.8×	29	1.6k
Laura M. Shireman United States	18	194 0.6×	207 1.2×	323 2.1×	93 0.6×	69 0.6×	36	1.0k
David B. Buckley United States	17	499 1.5×	397 2.4×	420 2.7×	178 1.2×	122 1.0×	21	1.2k
Wan Gyoon Shin South Korea	20	188 0.6×	118 0.7×	211 1.4×	197 1.3×	118 1.0×	62	1.2k
Anna Nordmark Sweden	15	247 0.8×	192 1.1×	137 0.9×	138 0.9×	92 0.8×	22	733

Countries citing papers authored by Jennifer E. Sager

Since Specialization

Citations

This map shows the geographic impact of Jennifer E. Sager's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jennifer E. Sager with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jennifer E. Sager more than expected).

Fields of papers citing papers by Jennifer E. Sager

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jennifer E. Sager. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jennifer E. Sager. The network helps show where Jennifer E. Sager may publish in the future.

Co-authorship network of co-authors of Jennifer E. Sager

This figure shows the co-authorship network connecting the top 25 collaborators of Jennifer E. Sager. A scholar is included among the top collaborators of Jennifer E. Sager based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jennifer E. Sager. Jennifer E. Sager is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Bailey, Kate, Jessica D. Briley, Tanya Duke‐Novakovski, et al.. (2025). The American College of Veterinary Anesthesia and Analgesia Small Animal Anesthesia and Sedation Monitoring Guidelines 2025. Veterinary Anaesthesia and Analgesia. 52(4). 377–385. 1 indexed citations

Subramanian, Raju, William Rowe, Michael Graupe, et al.. (2024). Pharmacokinetics, Disposition, and Biotransformation of [14C]Lenacapavir, a Novel, First-in-Class, Selective Inhibitor of HIV-1 Capsid Function, in Healthy Participants Following a Single Intravenous Infusion. Clinical Pharmacokinetics. 63(2). 241–253. 8 indexed citations

Sager, Jennifer E., Sergio Parra, Jennifer Moore, et al.. (2024). Pharmacokinetics of the Monoclonal Antibody, Sotrovimab, in Healthy Participants Following IM Administration at Different Injection Sites. Clinical Pharmacology & Therapeutics. 117(3). 759–767.

Sager, Jennifer E., Alessia Peter, Michael Schmid, et al.. (2024). A phase 1 study in healthy volunteers to investigate the safety, tolerability, and pharmacokinetics of VIR-2482: a monoclonal antibody for the prevention of severe influenza A illness. Antimicrobial Agents and Chemotherapy. 68(4). e0127323–e0127323. 4 indexed citations

Alexander, Elizabeth, Stephen A. Harrison, Marjan Hezareh, et al.. (2023). Pharmacokinetics, Safety, and Tolerability of Anti-SARS-CoV-2 Monoclonal Antibody, Sotrovimab, Delivered Intravenously or Intramuscularly in Japanese and Caucasian Healthy Volunteers. Clinical Pharmacokinetics. 63(1). 57–68. 2 indexed citations

Sager, Jennifer E., Julie Passarell, Xiaobin Li, et al.. (2023). Population pharmacokinetics and exposure‐response analysis of a single dose of sotrovimab in the early treatment of patients with mild to moderate COVID‐19. CPT Pharmacometrics & Systems Pharmacology. 12(6). 853–864. 5 indexed citations

Moya, Jaynier, Sergio Parra, Erick Stanley Petersen Juárez, et al.. (2023). Safety, Virology, Pharmacokinetics, and Clinical Experience of High-Dose Intravenous Sotrovimab for the Treatment of Mild to Moderate COVID-19: An Open-Label Clinical Trial. Open Forum Infectious Diseases. 10(7). ofad344–ofad344. 2 indexed citations

Austin, Daren, Jennifer E. Sager, Elizabeth Alexander, et al.. (2022). Safety and Pharmacokinetics of the Anti-SARS-CoV-2 Monoclonal Antibody, Sotrovimab, Administered by Intravenous Injection in Japanese and Caucasian Healthy Volunteers. Kansenshogaku zasshi. 96(2). 39–45. 1 indexed citations

Sager, Jennifer E., David K. Hong, Aurelio Bonavia, et al.. (2020). 631. Preliminary safety and pharmacokinetic profile of VIR-2482: a monoclonal antibody for the prevention of influenza A illness. Open Forum Infectious Diseases. 7(Supplement_1). S376–S376. 2 indexed citations

10.

Huang, Weize, Mariko Nakano, Jennifer E. Sager, Isabelle Ragueneau‐Majlessi, & Nina Isoherranen. (2017). Physiologically Based Pharmacokinetic Model of the CYP2D6 Probe Atomoxetine: Extrapolation to Special Populations and Drug-Drug Interactions. Drug Metabolism and Disposition. 45(11). 1156–1165. 30 indexed citations

11.

Wagner, David J., et al.. (2017). Interaction and Transport of Methamphetamine and its Primary Metabolites by Organic Cation and Multidrug and Toxin Extrusion Transporters. Drug Metabolism and Disposition. 45(7). 770–778. 31 indexed citations

12.

Sun, Yongkai, et al.. (2017). Quantitative Prediction of CYP3A4 Induction: Impact of Measured, Free, and Intracellular Perpetrator Concentrations from Human Hepatocyte Induction Studies on Drug-Drug Interaction Predictions. Drug Metabolism and Disposition. 45(6). 692–705. 22 indexed citations

13.

Sager, Jennifer E., Sasmita Tripathy, Lauren Price, et al.. (2016). In vitro to in vivo extrapolation of the complex drug-drug interaction of bupropion and its metabolites with CYP2D6; simultaneous reversible inhibition and CYP2D6 downregulation. Biochemical Pharmacology. 123. 85–96. 31 indexed citations

14.

Sager, Jennifer E., Lauren Price, & Nina Isoherranen. (2016). Stereoselective Metabolism of Bupropion to OH-bupropion, Threohydrobupropion, Erythrohydrobupropion, and 4′-OH-bupropion in vitro. Drug Metabolism and Disposition. 44(10). 1709–1719. 37 indexed citations

15.

Sager, Jennifer E., et al.. (2016). Identification and Structural Characterization of Three New Metabolites of Bupropion in Humans. ACS Medicinal Chemistry Letters. 7(8). 791–796. 18 indexed citations

16.

Sager, Jennifer E., Jingjing Yu, Isabelle Ragueneau‐Majlessi, & Nina Isoherranen. (2015). Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification. Drug Metabolism and Disposition. 43(11). 1823–1837. 384 indexed citations breakdown →

17.

Sager, Jennifer E., J. Lutz, R. Foti, et al.. (2014). Fluoxetine- and Norfluoxetine-Mediated Complex Drug–Drug Interactions: In Vitro to In Vivo Correlation of Effects on CYP2D6, CYP2C19, and CYP3A4. Clinical Pharmacology & Therapeutics. 95(6). 653–662. 57 indexed citations

18.

Shirasaka, Yoshiyuki, Jennifer E. Sager, Justin D. Lutz, Connie L. Davis, & Nina Isoherranen. (2013). Inhibition of CYP2C19 and CYP3A4 by Omeprazole Metabolites and Their Contribution to Drug-Drug Interactions. Drug Metabolism and Disposition. 41(7). 1414–1424. 87 indexed citations

19.

Smith, Erica D., et al.. (2008). Age- and calorie-independent life span extension from dietary restriction by bacterial deprivation in Caenorhabditis elegans. BMC Developmental Biology. 8(1). 49–49. 104 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact